// STATE LEGISLATION TRACKER

Texas SB 54 — Relating to the regulation of the cultivation, manufacture, processing, distribution, sale, testing, transportation, del

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Texas
Bill: SB 54
Filed: 2025-07-30
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Texas SB 54 appears to be about cannabis and cannabinoids, including their production, sale, testing, transport, possession, use, and taxation. Based on the title and subjects provided, it does not appear to directly affect compounded peptides, off-label prescribing, telehealth peptide care, clinician scope, FDA 503A/503B compounding, controlled substances for peptides, or prescription monitoring for peptide therapies.

Key Points

No direct peptide access issue is visible from the bill title
This appears focused on cannabis and cannabinoid regulation
No clear change to compounding pharmacies or 503A/503B rules
No visible change to NP, naturopathic, or telehealth peptide practice

What to Watch For

Note Confirm the full bill text if it mentions broader controlled-substance or prescribing rules beyond cannabis.

Note Watch whether cannabis-related testing or dispensing rules are later copied into other health-product categories.

Where the Bill Stands

The provided OpenStates metadata says the latest action refetch failed, so the bill's current procedural status is unknown.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws